PMID- 24485801
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20211203
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 12
IP  - 4
DP  - 2014 Aug
TI  - A population-based overview of sequences of targeted therapy in metastatic renal 
      cell carcinoma.
PG  - e127-31
LID - S1558-7673(13)00314-5 [pii]
LID - 10.1016/j.clgc.2013.12.003 [doi]
AB  - BACKGROUND: Several TTs are available to treat mRCC; however, the optimal 
      sequence of therapy remains unknown. PATIENTS AND METHODS: Consecutive 
      population-based samples of patients with mRCC treated with TT were collected 
      from 12 cancer centers via the International Metastatic Renal Cell Carcinoma 
      Database Consortium. Patient characteristics, first-line and second-line 
      progression-free survival rates and overall survival data were collected based on 
      sequencing of TT. Multivariable analysis was performed when there were 
      significant differences on univariable analysis. RESULTS: A total of 2106 
      patients were included with a median follow-up of 36 months; 907 (43%) and 318 
      (15%) patients received subsequent second-line and third-line TT, respectively. 
      Baseline characteristics were well matched among different sequences apart from 
      more patients with non-clear-cell histology in the vascular endothelial growth 
      factor (VEGF) to mammalian target of rapamycin (mTOR) group compared with the 
      VEGF to VEGF group sequence. When adjusting for the Heng risk criteria and 
      non-clear-cell histology, the hazard ratio for death for the VEGF to mTOR group 
      versus the VEGF to VEGF group was 0.833 (95% confidence interval [CI], 
      0.669-1.037; P = .1016). More specifically, the adjusted hazard ratio for death 
      for the sunitinib to everolimus versus sunitinib to temsirolimus sequences was 
      0.774 (95% CI, 0.52-1.153; P = .2086). CONCLUSION: In this large multicenter 
      analysis evaluating different sequences of TT in mRCC, no substantial effect on 
      outcome based on sequence of TT was identified.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Alimohamed, Nimira
AU  - Alimohamed N
AD  - Princess Margaret Hospital, Toronto, Ontario, Canada. Electronic address: 
      nimira.alimohamed@uhn.ca.
FAU - Lee, Jae-Lyn
AU  - Lee JL
AD  - Asan Medical Centre, Seoul, South Korea.
FAU - Srinivas, Sandy
AU  - Srinivas S
AD  - Stanford Cancer Centre, Stanford, CA.
FAU - Bjarnason, Georg A
AU  - Bjarnason GA
AD  - Sunnybrook Odette Cancer Institute, Toronto, Ontario, Canada.
FAU - Knox, Jennifer J
AU  - Knox JJ
AD  - Princess Margaret Hospital, Toronto, Ontario, Canada.
FAU - Mackenzie, Mary J
AU  - Mackenzie MJ
AD  - London Health Sciences Center, London, Ontario, Canada.
FAU - Wood, Lori
AU  - Wood L
AD  - Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada.
FAU - Vaishampayan, Ulka N
AU  - Vaishampayan UN
AD  - Wayne State University, Detroit, MI.
FAU - Tan, Min-Han
AU  - Tan MH
AD  - National Cancer Center, Institute of Bioengineering and Nanotechnology, 
      Singapore.
FAU - Rha, Sun Young
AU  - Rha SY
AD  - Yonsei University Hospital, Seoul, South Korea.
FAU - Donskov, Frede
AU  - Donskov F
AD  - Aarhus University Hospital, Aarhus, Denmark.
FAU - Tantravahi, Srinivas
AU  - Tantravahi S
AD  - Huntsman Cancer Institute, Salt Lake City, UT.
FAU - Kollmannsberger, Christian
AU  - Kollmannsberger C
AD  - BC Cancer Agency, Vancouver, British Columbia, Canada.
FAU - North, Scott
AU  - North S
AD  - Cross Cancer Institute, Edmonton, Alberta, Canada.
FAU - Rini, Brian I
AU  - Rini BI
AD  - Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AD  - Dana-Farber Cancer Institute, Harvard University, Boston, MA.
FAU - Heng, Daniel Y C
AU  - Heng DY
AD  - Tom Baker Cancer Centre, Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
DEP - 20131227
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 0 (Antineoplastic Agents)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/metabolism/mortality/secondary
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/metabolism/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - *Molecular Targeted Therapy
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
OTO - NOTNLM
OT  - Kidney cancer
OT  - Mammalian target of rapamycin
OT  - Sequencing
OT  - Treatment
OT  - Vascular endothelial growth factor
EDAT- 2014/02/04 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/02/04 06:00
PHST- 2013/09/09 00:00 [received]
PHST- 2013/11/22 00:00 [revised]
PHST- 2013/12/23 00:00 [accepted]
PHST- 2014/02/04 06:00 [entrez]
PHST- 2014/02/04 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - S1558-7673(13)00314-5 [pii]
AID - 10.1016/j.clgc.2013.12.003 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2014 Aug;12(4):e127-31. doi: 10.1016/j.clgc.2013.12.003. 
      Epub 2013 Dec 27.